Comparing Urine Tests and Frequent Cystoscopy for Monitoring Early-Stage Non-Muscle Invasive Bladder Cancer

What this Trial Is About

Researchers are evaluating ways to improve bladder cancer monitoring by replacing some cystoscopy procedures with urine testing in patients with early-stage non-muscle invasive bladder cancer. This randomized phase 2 study involves 240 participants and aims to compare urinary symptoms, discomfort, anxiety, complications, cancer recurrence, and progression among different monitoring approaches. Participants will be assigned to one of three groups frequent cystoscopy, Xpert urine test, or Bladder EpiCheck urine test. The frequent cystoscopy group will have cystoscopy procedures at 6, 12, 18, and 24 months. The Xpert and EpiCheck groups will have urine tests and doctor check-ups at 6 and 18 months, with cystoscopy at 12 and 24 months. The study period for monitoring is 24 months. During the study, participants will complete quality of life questionnaires at 3, 6, 12, 18, and 24 months to assess urinary quality of life. Researchers will monitor urinary symptoms, number of invasive procedures, anxiety, and cancer outcomes. Follow-up includes multiple assessments over two years to evaluate the impact of different surveillance methods on patient well-being and cancer management.

Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance